ARS Pharmaceuticals (SPRY) Non-Current Assets (2020 - 2026)

ARS Pharmaceuticals has disclosed Non-Current Assets across 7 years of filings, most recently posting $42.3 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $42.3 million, up 80.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $151.1 million (up 200.0% YoY), and the FY2025 annual result was $42.8 million, up 153.62% from the prior year.
• Non-Current Assets came in at $42.3 million for Q1 2026 at ARS Pharmaceuticals, down from $42.8 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $51.1 million in Q1 2022 to a low of $265000.0 in Q3 2022.
• The 5-year median for Non-Current Assets is $8.8 million (2024), against an average of $17.8 million.
• Across the five-year window, Non-Current Assets sank 99.44% in 2022 and jumped 2508.79% in 2025, its largest moves.
• ARS Pharmaceuticals' Non-Current Assets stood at $3.7 million in 2022, then sank by 60.86% to $1.5 million in 2023, then soared by 1053.08% to $16.9 million in 2024, then soared by 153.62% to $42.8 million in 2025, then decreased by 0.98% to $42.3 million in 2026.
• The last three Non-Current Assets figures came in at $42.3 million (Q1 2026), $42.8 million (Q4 2025), and $33.9 million (Q3 2025), per Business Quant data.